In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models

BACKGROUND: Dendritic cells (DCs) are a promising therapeutic target in cancer immunotherapy given their ability to prime antigen-specific T cells, and initiate antitumor immune response. A major obstacle for DC-based immunotherapy is the difficulty to obtain a sufficient number of functional DCs. T...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Oba, Takaaki, Makino, Kenichi, Kajihara, Ryutaro, Yokoi, Toshihiro, Araki, Ryoko, Abe, Masumi, Minderman, Hans, Chang, Alfred E, Odunsi, Kunle, Ito, Fumito
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2021
Matèries:
Oncolytic and Local Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8166607/
https://ncbi.nlm.nih.gov/pubmed/34049930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002432
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars